UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Engineering antibodies for clinical applications in cancer

Chester, K; Pedley, B; Tolner, B; Violet, J; Mayer, A; Sharma, S; Boxer, G; ... Begent, R; + view all (2004) Engineering antibodies for clinical applications in cancer. TUMOR BIOL , 25 (1-2) 91 - 98. 10.1159/000077727.

Full text not available from this repository.

Abstract

The 'magic bullet' concept predicted over a century ago that antibodies would be used to target cancer therapy. Since then initial problems that were related to specificity, purity and immungenicity of antibody-based reagents have slowly been overcome due to developments in technology and increased knowledge. As a result, antibodies are in use for many clinical applications and now comprise the second largest category of medicines in clinical development after vaccines. For antibody-based cancer therapeutics the last 20 years have met with an explosion of knowledge about the biology of the disease and potential targets as well as new technology which allows cloning and manipulation of multifunctional antibody-based molecules. However, the focus still remains on developing therapeutics that will have potential for treating cancer in people and this is efficiently assessed in mechanistic clinical trials that feed back to the laboratory for further development. This review illustrates the mechanistic approach to making new molecules for antibody imaging and therapy of cancer. It is illustrated by examples of radioimmunotherapy and antibody-directed enzyme prodrug therapy developed by the authors. Copyright (C) 2004 S. Karger AG, Basel.

Type: Article
Title: Engineering antibodies for clinical applications in cancer
DOI: 10.1159/000077727
Keywords: antibody, single-chain Fv, antibody-directed enzyme rodrug therapy, radioimmunotherapy, cancer, clinical trials, CHAIN FV ANTIBODY, ENZYME PRODRUG THERAPY, FUSION PROTEIN, CARCINOEMBRYONIC ANTIGEN, COLORECTAL-CARCINOMA, MANNOSE RECEPTOR, TUMOR, RADIOIMMUNOTHERAPY, EFFICACY, INNATE
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/114429
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item